A pivotal, Phase III trial of epacadostat in combination with pembrolizumab in patients with first-line non-small cell lung cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 04 May 2017
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 04 May 2017 According to an Incyte Corporation media release, this trial is expected to initiate in 2017.
- 07 Apr 2017 New trial record
- 31 Mar 2017 This trial will be conducted under the expanded collaboration for seven pivotal trials of Epacadostat and KEYTRUDA (pembrolizumab) between an Incyte Corporation and Merck, as reported in an Incyte Corporation media release.